Geschäftskunden Kundenprogramme
Vor Ort
Merkzettel Warenkorb
  • Produktbild: Psychopharmacoendocrinology and Depression Research
  • Produktbild: Psychopharmacoendocrinology and Depression Research

Psychopharmacoendocrinology and Depression Research

Fr. 137.00

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

05.10.1990

Verlag

Springer Berlin

Seitenzahl

219

Maße (L/B/H)

23.5/15.5/1.3 cm

Gewicht

340 g

Sprache

Englisch

ISBN

978-3-540-52075-7

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

05.10.1990

Verlag

Springer Berlin

Seitenzahl

219

Maße (L/B/H)

23.5/15.5/1.3 cm

Gewicht

340 g

Sprache

Englisch

ISBN

978-3-540-52075-7

Herstelleradresse

Springer-Verlag GmbH
Tiergartenstr. 17
69121 Heidelberg
DE

Email: ProductSafety@springernature.com

Kundinnen und Kunden meinen

0 Bewertungen

Informationen zu Bewertungen

Zur Abgabe einer Bewertung ist eine Anmeldung im Konto notwendig. Die Authentizität der Bewertungen wird von uns nicht überprüft. Wir behalten uns vor, Bewertungstexte, die unseren Richtlinien widersprechen, entsprechend zu kürzen oder zu löschen.

Die Bewertungen sind nach Format, Anzahl Sterne und Datum sortiert.

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kund*innen durch Ihre Meinung

Kundinnen und Kunden meinen

0 Bewertungen filtern
  • Produktbild: Psychopharmacoendocrinology and Depression Research
  • Produktbild: Psychopharmacoendocrinology and Depression Research
  • 1 Introduction.- 1.1 Outline of the Study.- 1.2 Effect of Psychotropic Drugs on Central Nervous Aminergic Stimuli Transmission.- 1.3 Influence of Aminergic Neuronal Systems on Anterior Pituitary Hormone Secretion.- 1.4 Aminergic Neurons, APH Secretion and Depression Research.- 2 Influence of Psychotropic Drugs on Anterior Pituitary Hormone Secretion in Healthy Subjects.- 2.1 Healthy Subjects and Methods.- 2.2 Influence of Psychotropic Drugs on GH Secretion.- 2.2.1 Antidepressants and GH Secretion.- 2.2.1.1 Desipramine.- 2.2.1.2 Clomipramine.- 2.2.1.3 Nomifensine.- 2.2.1.4 L- and D-Oxaprotiline.- 2.2.1.5 Bupropion.- 2.2.1.6 Indalpine.- 2.2.1.7 Summary.- 2.2.2 Neuroleptics and GH Secretion.- 2.2.2.1 Haloperidol.- 2.2.2.2 Summary.- 2.2.3 Benzodiazepine Derivatives and GH Secretion.- 2.2.3.1 Diazepam and Metaclazepam.- 2.2.3.2 Summary.- 2.2.4 Discussion.- 2.3 Influence of Psychotropic Drugs on Prolactin Secretion.- 2.3.1 Antidepressants and PRL Secretion.- 2.3.1.1 Desipramine.- 2.3.1.2 Clomipramine.- 2.3.1.3 Nomifensine.- 2.3.1.4 L- and D-Oxaprotiline.- 2.3.1.5 Bupropion.- 2.3.1.6 Indalpine.- 2.3.1.7 Summary.- 2.3.2 Neuroleptics and PRL Secretion.- 2.3.2.1 Haloperidol.- 2.3.2.2 Summary.- 2.3.3 Benzodiazepine Derivatives and PRL Secretion.- 2.3.3.1 Diazepam.- 2.3.3.2 Summary.- 2.3.4 Discussion.- 2.4 Influence of Psychotropic Drugs on Cortisol/ACTH Secretion.- 2.4.1 Antidepressants and Cortisol/ACTH Secretion.- 2.4.1.1 Desipramine.- 2.4.1.2 Clomipramine.- 2.4.1.3 L- and D-Oxaprotiline.- 2.4.1.4 Indalpine.- 2.4.1.5 Summary.- 2.4.2 Neuroleptics and Cortisol Secretion.- 2.4.2.1 Sulpiride.- 2.4.2.2 Summary.- 2.4.3 Benzodiazepine Derivatives and Cortisol/ACTH Secretion.- 2.4.3.1 Diazepam.- 2.4.3.2 Summary.- 2.4.4 Discussion.- 2.5 Discussion.- 3 Influence of Receptor Blockers and Receptor Agonists on Antidepressant-Induced Anterior Pituitary Hormone Secretion in Healthy Subjects.- 3.1 Healthy Subjects and Methods.- 3.2 Influence of Receptor Blockers and Receptor Agonists on DMI-Induced GH Stimulation.- 3.2.1 GH, DMI, and Methysergide.- 3.2.2 GH, DMI, and Phentolamine.- 3.2.3 GH, DMI, and Yohimbin.- 3.2.4 GH, DMI, and Prazosin.- 3.2.5 GH, DMI, and Propranolol.- 3.2.6 GH, DMI, and Clenbuterol.- 3.2.6 Summary.- 3.3 Influence of Receptor Blockers and Receptor Agonists on DMI-Induced PRL Stimulation.- 3.3.1 PRL, DMI, and Methysergide.- 3.3.2 PRL, DMI, and Phentolamine.- 3.3.3 PRL, DMI, and Yohimbin.- 3.3.4 PRL, DMI, and Prazosin.- 3.3.5 PRL, DMI, and Propranolol.- 3.3.6 PRL, DMI, and Clenbuterol.- 3.3.7 Summary.- 3.4 Influence of Receptor Blockers and Receptor Agonists on DMI-Induced Cortisol/ACTH Stimulation.- 3.4.1 Cortisol, DMI, and Methysergide.- 3.4.2 Cortisol, DMI, and Phentolamine.- 3.4.3 Cortisol, DMI, and Yohimbin.- 3.4.4 Cortisol, ACTH, DMI, and Prazosin.- 3.4.5 Cortisol, DMI, and Propranolol.- 3.4.6 Cortisol, DMI, and Clenbuterol.- 3.4.7 Summary.- 3.5 Discussion.- 4 Desipramine-Induced Growth Hormone Stimulation in Depressive Patients and Healthy Subjects.- 4.1 GH Secretion after Desipramine in Depressive Patients and Healthy Subjects.- 4.2 Healthy Subjects, Patients, and Methods.- 4.2.1 GH Secretion after DMI in Male and Female Healthy Subjects of Differing Age.- 4.2.2 Case Records of the Patients.- 4.2.3 Selection of the Patients.- 4.2.4 Evaluation of the Trial Group.- 4.3 Results.- 4.3.1 Healthy Male and Female Subjects.- 4.3.1.1 GH Secretion after DMI in Healthy Male Subjects Grouped According to Their Age in Decades.- 4.3.1.2 GH Secretion after DMI in Healthy Female Subjects Grouped According to Their Age in Decades.- 4.3.1.3 GH Secretion after DMI in Healthy Female Subjects in Relationship to the Menstrual Cycle.- 4.3.1.4 Summary.- 4.3.2 GH Secretion after Administration of DMI in Male and Female Patients.- 4.3.2.1 Severity of the Depressive Disease (Hamilton Depression Scale) and GH Secretion.- 4.3.2.2 GH Secretion after DMI in Depressive Patients (Grouped According to Diagnosis) in Comparison with Healthy Subjects.- 4.3.2.2.1 Monopolar Endogenous Depressive Male Patients (ICD 296.1).- 4.3.2.2.2 Bipolar Endogenous Depressive Male Patients (ICD 296.3).- 4.3.2.2.3 Neurotic Depressive Male Patients (ICD 300.4).- 4.3.2.2.4 Monopolar Endogenous Depressive Female Patients (ICD 296.1).- 4.3.2.2.5 Bipolar Endogenous Depressive Female Patients (ICD 296.3).- 4.3.2.2.6 Neurotic Depressive Female Patients (ICD 300.4).- 4.3.2.3 Summary.- 4.3.3 Group Comparison of GH Secretion after DMI and DMI-Induced GH Stimulation in Patients and Healthy Subjects.- 4.3.3.1 GH Secretion Reflected in the AUCs after DMI in Male Patients and in Healthy Male Subjects.- 4.3.3.2 GH Secretion Reflected in the AUCs after DMI in Female Patients and Healthy Female Subjects.- 4.3.3.3 GH Stimulation 60 min after DMI in Male Patients in Comparison with Healthy Male Subjects.- 4.3.3.4 GH Stimulation 60 min after DMI in Female Patients in Comparison with Healthy Female Subjects.- 4.4 Summary and Discussion.- 5 Summary.- 6 Reference.